Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/104692ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF
WO 27.05.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2020/130409 Applicant BLISS BIOPHARMACEUTICAL (HANGZHOU) CO., LTD. Inventor XIA, Bing
An isolated IgG antibody includes two identical heavy chains each having a hinge region with an amino acid sequence containing an additional cysteine upstream of the two cysteines in the CPPCP sequence of a native IgG hinge region, and a CH1 domain containing a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs based on the antibody having this architecture are also provided.
2.WO/2022/105787LONG ACTING BI-SPECIFIC T CELL ENGAGERS TARGETING CD3 AND CD47
WO 27.05.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/CN2021/131181 Applicant SHENZHEN ENDURING BIOTECH, LTD. Inventor WEN, Yu
Provided are bispecific molecules and, in particular, long acting bispecific T cell engagers targeting CD3 and CD47 with improved efficacy, toxic profile and therapeutic window, and methods of making and using such long acting bispecific binding molecules.
3.WO/2022/105817BI-FUNCTIONAL MOLECULES
WO 27.05.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2021/131389 Applicant SUZHOU TRANSCENTA THERAPEUTICS CO., LTD. Inventor QIAN, Xueming
Provided are proteins comprising a PD- L1-binding moiety linked to a TGFβ-binding moiety, IL-1-binding moiety, immunostimulatory polypeptides (e.g., soluble LAG3 or soluble CD4) or CD47-binding moiety, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same and the uses thereof.
4.WO/2022/105832ANTI-PD-L1 NANOBODY AND TRIFUNCTIONAL FUSION PROTEIN
WO 27.05.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/131479 Applicant QURE BIOTECHNOLOGY (SHANGHAI) CO., LTD. Inventor QU, Xiangdong
The present invention relates to an anti-PD-L1 nanobody and a trifunctional fusion protein. The anti-PD-L1 nanobody and an Fc fusion protein thereof are strong in specificity, high in affinity, and weak in immunogenicity in humans, and has a remarkable anti-tumor effect. The trifunctional fusion protein comprises a TGF-β inhibitor, a VEGF inhibitor and a PD-L1 inhibiting antibody, and has a very high affinity for both a human VEGF protein and a TGF-β protein and also a good affinity for a human PD-L1 protein; moreover, the trifunctional fusion protein can also block the binding of the human PD-1/PD-L1 protein.
5.WO/2022/108877DEPLETING MONOCLONAL ANTIBODIES AGAINST NATURAL KILLER CELLS
WO 27.05.2022
Int.Class C12N 5/0783
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
Appl.No PCT/US2021/059383 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor LANIER, Lewis L.
Anti-CD94 antibodies and their use are described.
6.WO/2022/109102NAV1.7 BINDERS
WO 27.05.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2021/059842 Applicant MERCK SHARP & DOHME CORP. Inventor ABEYWICKREMA, Pravien Damitha
Antibodies and antigen-binding fragments thereof that bind the human voltage-gated sodium channel Nav1.7α protein subunit (Nav1.7 binders) are described. In particular embodiments, the Nav1.7 binders comprise a heavy-chain immunoglobulin single variable domain (ISVD or VHH).
7.WO/2022/107136METHODS AND BIOMARKERS FOR DIAGNOSTICS, DISEASE MONITORING, PERSONALIZED DRUG DISCOVERY AND TARGETED THERAPY IN GLIOMA PATIENTS
WO 27.05.2022
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No PCT/IL2021/051370 Applicant BAR-ILAN UNIVERSITY Inventor FRENKEL-MORGENSTERN, Milana
Novel powerful methods for identifying, monitoring, and treating conditions associated with omics-discoverable features in human subjects, and particularly conditions such as malignant tumors are provided.
8.WO/2022/109227COMBINED CANCER THERAPY OF B7-H3 AND CD47 IMMUNE CHECKPOINT INHBITIOR AND METHODS OF USE
WO 27.05.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/US2021/060025 Applicant ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Inventor CELEBI, Julide Tok
The present disclosure generally relates to compositions and methods for treating a solid tumor in a subject, wherein administering compositions having a combination of an inhibitor of B7-H3 (CD276) and an inhibitor of CD47-SIRPα can inflame a cold tumor microenvironment.
9.WO/2022/109317ANTI-INFLUENZA ANTIBODIES AND COMBINATIONS THEREOF
WO 27.05.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/060166 Applicant VIR BIOTECHNOLOGY, INC. Inventor CORTI, Davide
The present disclosure relates, in part, to anti-influenza antibodies (and antigenbinding fragments thereof) and combinations thereof for preventing and treating influenza infection. Presently disclosed combinations provide surprising synergistic effects and can potently prevent, inhibit, or neutralize an influenza infection, such as an influenza A virus (IAV) infection an influenza B virus (IBV) infection, or both.
10.WO/2022/105881ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF
WO 27.05.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/131791 Applicant BLISS BIOPHARMACEUTICAL (HANGZHOU) CO., LTD. Inventor XIA, Bing
Isolated anti-human CD73 antibody includes two heavy chains each including a hinge region comprising an amino acid sequence of that allow site-specific conjugation of cytotoxic drugs. Each heavy chain can include a human CH1 domain located upstream of and connected to the hinge region. The CH1 domain comprising a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs containing the antibody conjugated with a cytotoxic drug are also provided. Pharmaceutical compositions including the antibody or the ADCs, and methods of treating cancer using the pharmaceutical compositions are also provided.